Opus Genetics, Inc.

IRD ·Healthcare, Drug Manufacturers - General, United States
Financial Statements Balance Sheet
Annual Quarterly

Balance Sheet

Line Item Jun 2026 Mar 2026 Dec 2025 Sep 2025 Jun 2025 Mar 2025 Dec 2024 Sep 2024
Assets
Cash & Equivalents $88.8M $60.0M $45.1M $30.8M $32.4M $41.8M $30.3M $36.6M
Accounts Receivable $1.0M $1.7M $2.0M $2.9M $3.4M $3.1M $3.6M $1.9M
Inventory
Total Current Assets $92.7M $66.6M $50.0M $35.9M $38.4M $47.9M $36.6M $40.4M
Property, Plant & Equipment $172.0K $186.0K $199.0K $212.0K $226.0K $239.0K $252.0K $0
Goodwill
Intangible Assets (Excl. Goodwill)
Total Assets $93.0M $66.8M $50.2M $36.1M $38.7M $48.2M $36.9M $40.4M
Liabilities
Accounts Payable $1.9M $4.4M $3.3M $2.4M $1.5M $2.4M $3.1M $844.0K
Total Current Liabilities $7.6M $9.3M $7.8M $29.1M $20.2M $24.3M $11.3M $6.1M
Long-Term Debt $35.3M $1.2M $1.1M $1.1M $1.0M $0
Total Liabilities $106.0M $87.9M $34.9M $30.2M $21.2M $24.3M $11.3M $6.1M
Stockholders' Equity
Retained Earnings $-262.2M $-254.1M $-188.6M $-172.1M $-154.6M $-147.2M $-139.0M $-103.9M
Total Stockholders' Equity $-13.0M $-45.8M $15.3M $6.0M $17.5M $5.1M $6.7M $34.3M
← Newer Page 1 of 8 Older →